Loading…
Hamps Bio (BSE 544312)₹25.95+1.76%Other Agricultural Products
In the Mar 2026 quarter (consolidated), Hamps Bio reported sales of ₹44.63 Cr, up 43.2% from Mar 2025, and net profit of −₹5.41 Cr, down 1,790.6% year on year. For the year to Mar 2026, sales were ₹84.38 Cr and net profit −₹7.37 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 31.17 | 44.63 |
| Expenses | 29.00 | 46.21 |
| Operating Profit | 2.23 | −1.50 |
| OPM % | 7.1% | −3.3% |
| Other Income | 0.68 | 2.95 |
| Interest | 0.60 | 1.37 |
| Depreciation | 1.89 | 5.17 |
| Profit before tax | 0.41 | −5.04 |
| Tax % | 23.8% | 7.3% |
| Net Profit | 0.32 | −5.41 |
| EPS (Rs) | 0.37 | −6.20 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 66.43 | 84.38 |
| Expenses | 58.84 | 84.21 |
| Operating Profit | 7.71 | 0.35 |
| OPM % | 11.6% | 0.4% |
| Other Income | 1.52 | 3.33 |
| Interest | 1.41 | 2.50 |
| Depreciation | 3.78 | 8.20 |
| Profit before tax | 4.03 | −6.98 |
| Tax % | 26.5% | 5.6% |
| Net Profit | 2.97 | −7.37 |
| EPS (Rs) | 3.41 | −8.45 |
| Dividend payout % | 0.0% | 0.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 4.34 | 8.71 |
| Reserves | 4.45 | −0.62 |
| Borrowings | 2.98 | 6.91 |
| Other Liabilities | 1.03 | 0.95 |
| Total Liabilities | 12.80 | 15.95 |
| Fixed Assets | 2.60 | 9.12 |
| CWIP | 3.29 | 1.09 |
| Investments | 0.00 | 0.08 |
| Other Assets | 6.91 | 5.66 |
| Inventories | 2.39 | 2.59 |
| Trade receivables | 1.20 | 1.60 |
| Cash & equivalents | 0.11 | 0.18 |
| Total Assets | 12.80 | 15.95 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | −1.78 | 1.53 |
| Cash from investing activity | −6.23 | −2.87 |
| Cash from financing activity | 7.99 | 3.71 |
| Net cash flow | 0.04 | 2.39 |
| Capex | 3.73 | 5.14 |
| Free cash flow | −5.48 | −3.60 |
| CFO / OP % | −24.1% | 446.9% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 7 | 7 |
| Inventory days | 42 | 29 |
| Days payable | 12 | 5 |
| Cash conversion cycle | 40 | 34 |
| Working capital days | 12 | 6 |
| ROCE % | — | −33.7% |
For the Mar 2026 quarter, Hamps Bio reported sales of ₹44.63 Cr, up 43.2% year on year and net profit of −₹5.41 Cr, down 1,790.6% year on year. The operating margin was −3.3%.
Hamps Bio's sales for the year to Mar 2026 were ₹84.38 Cr.
Net profit for the year to Mar 2026 was −₹7.37 Cr. Earnings per share over the same trailing period were ₹−8.45.
Hamps Bio reported borrowings of ₹6.91 Cr at Mar 2026, against cash and equivalents of ₹0.18 Cr.
Cash from operations was ₹1.53 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹3.60 Cr.